Gilead Sciences | GILD - Equity Capital And Reserves

Stock Price
130.48
Daily Change
0.81 0.62%
Monthly
-3.97%
Yearly
19.59%
Q2 Forecast
126.98

Gilead Sciences reported $23.52B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.65B 394.9M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.62B 455.37M Mar/2026
J&J USD 81.19B 358M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026